Back to top

Repligen–BioLife Deal: Market, Integration and Regulatory Risks Threaten Growth Outlook and Shareholder Returns

Repligen (RGEN) has disclosed a new risk, in the Corporate Activity and Growth category. Repligen faces meaningful risk that its assumptions about ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Repligen Corporation (RGEN)